Clinical Trial Update: Half-Dose Intracoronary Abciximab Bolus Improves the Mortality Outcome Compared to Standard Intravenous Regimen [Phase 4]

View source ↗

Summary

In a Phase 4 trial, a half-dose intracoronary abciximab bolus showed improved mortality outcomes versus the standard intravenous regimen, though the study was t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• Myocardial Infarction

Drugs mentioned

• Abciximab (abciximab)

Snippet

Sponsor: Azienda Sanitaria Ospedaliera | Conditions: Coronary Disease, Myocardial Infarction | Phase 4 | Status: TERMINATED